Related Experiment Video
Updated: Nov 5, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-Analysis of
Yu-Xiang Long1, Di-Yu Cui, Xue Kuang
1Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Insights
Levosimendan improves heart function in heart failure patients by enhancing both systolic and diastolic parameters in both ventricles. This meta-analysis confirms its positive effects on cardiac function, particularly evident in echocardiographic measurements.
Area of Science:
- Cardiology
- Pharmacology
- Medical Imaging
Background:
- Levosimendan is a calcium sensitizer used for inotropic support in heart failure.
- Echocardiography is crucial for assessing cardiac function, yet limited studies explore levosimendan's effects using this modality.
Purpose of the Study:
- To conduct a meta-analysis of randomized controlled trials evaluating levosimendan's impact on cardiac function via echocardiography.
- To systematically pool echocardiographic parameters to quantify levosimendan's effects on ventricular function in heart failure.
Main Methods:
- A comprehensive literature search was performed across PubMed, Embase, and CENTRAL databases up to August 2020.
- Included were 29 randomized controlled trials involving 574 heart failure patients, with data extracted on 14 echocardiographic parameters.
- A random-effect model was used to pool effect estimates for various cardiac function indices.
Main Results:
- Levosimendan reduced left ventricular diastolic dysfunction, indicated by decreased early/late transmitral flow velocity ratio and E/e'.
- Right ventricular systolic function improved, shown by increased tricuspid annular plane systolic excursion and peak systolic velocity, alongside reduced systolic pulmonary artery pressure.
- Right ventricular diastolic function showed improvements with decreased Aa and increased Ea and Ea/Aa ratios.
Conclusions:
- Levosimendan demonstrates a significant amelioration of both diastolic and systolic functions in both left and right ventricles of heart failure patients.
- The findings support levosimendan's role in improving overall cardiac performance in heart failure, as evidenced by comprehensive echocardiographic analysis.
Abstract:
Levosimendan, a calcium sensitizer, exerts inotropic action through improving left ventricular ejection fraction. We noticed that only few clinical studies are published in which the effects of levosimendan on cardiac function are studied by echocardiography. When screening the literature (PubMed, Embase, and CENTRAL, from inception to August 2020), we found 29 randomized controlled trials on levosimendan containing echocardiographic data. We included those studies, describing a total of 574 heart failure patients, in our meta-analysis and extracted 14 ultrasonic parameters, pooling the effect estimates using a random-effect model. Our analysis of the diastolic parameters of the left ventricle shows that levosimendan reduce the early/late transmitral diastolic peak flow velocity ratio [standardized mean difference (SMD) -0.45 to 95% confidence interval (CI) (-0.87 to -0.03), P = 0.037] and E/e' (e': mitral annulus peak early diastolic wave velocity using tissue-doppler imaging) [SMD -0.59, 95% CI (-0.8 to -0.39), P < 0.001]. As it regards the systolic parameters of the right ventricle, levosimendan increased tricuspid annular plane systolic excursion [SMD 0.62, 95% CI (0.28 to 0.95), P < 0.001] and tricuspid annular peak systolic velocity [SMD 0.75, 95% CI (0.35 to 1.16), P < 0.001], and reduced systolic pulmonary artery pressure [SMD -1.02, 95% CI (-1.32, -0.73), P < 0.001]. As it regards the diastolic parameters of the right ventricle, levosimendan was associated with the decrease of Aa (peak late diastolic tricuspid annular velocity using tissue-doppler imaging) [SMD -0.38, 95% CI (-0.76 to 0), P = 0.047] and increase of Ea (peak early diastolic tricuspid annular velocity using tissue-doppler imaging) [SMD 1.03, 95% CI (0.63 to 1.42), P < 0.001] and Ea/Aa [SMD 0.86, 95% CI (0.18 to 1.54), P = 0.013]. We show that levosimendan is associated with an amelioration in the diastolic and systolic functions of both ventricles in heart failure patients.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Diuretics
Heart Failure Drugs: β-Blockers
Heart Failure V: Medical Management
Heart Failure II: Pathophysiology

